Microbiome
Gut microbes, blood metabolites, and metabolic traits
Open access · cc by · source: Europe PMC
In 531 METSIM men, gut microbiota associate with plasma metabolites and metabolic-syndrome-relevant traits.
Study at a glance
- Design
- Cross-sectional — METSIM subset microbiome–metabolite–metabolic trait association analysis
- N
- N=531 · 531 middle-aged Finnish men from the METSIM cohort (parent cohort 10,197)
- Population
- Middle-aged Finnish men in METSIM
- Outcome
- Associations of gut microbiota with plasma metabolites and metabolic traits
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Gut microbes relate to host plasma metabolites and metabolic traits, supporting microbiota as a factor alongside genetics and lifestyle.
Methodology
Systematically analyzed gut microbiome and metabolically relevant traits in a METSIM subset of Finnish men.
Limitations
Associations in middle-aged men are not universal causal proof or a treatment RCT.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Genetic instruments for gut taxa link a small set of microbiome–cancer associations under Mendelian randomisation.
Using Mendelian randomisation on gut-taxa genetic instruments, eleven stringent microbiome-to-cancer associations were reported (for example higher breast-cancer odds with Actinobacteria/Bifidobacteriales signals; Tyzzerella3 linked with higher lung adenocarcinoma but lower colorectal cancer risk).
Scope note — different outcome — metabolic traits/metabolites, not cancer
Limits the claim's scope: a different population, assay, or outcome.
Before type 1 diabetes autoimmunity, Bacteroides dorei can dominate children’s gut communities.
In children who later developed type 1 diabetes autoimmunity, Bacteroides dorei became dominant in the gut community before persistent autoantibodies (mean diagnosis age about 16.8 months).
Scope note — different population — middle-aged metabolic traits, not autoimmunity onset
Limits the claim's scope: a different population, assay, or outcome.
In middle-aged men, gut composition associates with metabolites and metabolic-syndrome traits.
In middle-aged men, gut microbiota composition was associated with plasma metabolites and metabolic-syndrome–related traits, placing the microbiome alongside genetics and lifestyle as a correlated host factor.
Evidence for the claim as stated.
Cancer MR, pediatric T1D timing, and adult metabolic-trait associations all involve gut microbiota, but they answer different disease and design questions. Treating them as one interchangeable “gut microbiome disease effect” collapses distinct estimands.
Evidence for the claim as stated.
Gut microbiota composition associates with metabolites and metabolic-syndrome traits.
In middle-aged men, gut microbiota composition was associated with plasma metabolites and metabolic-syndrome–related traits, placing the microbiome beside—not instead of—insulin-resistance physiology.
Evidence for the claim as stated.
Microbiome–metabolite associations in METSIM men and clamp/MRS insulin-resistance phenotypes share metabolic-syndrome territory while measuring different exposures and outcomes.
Evidence for the claim as stated.
Gut microbiota composition associates with metabolites and MetS-related traits in men.
In middle-aged men, gut microbiota composition associated with plasma metabolites and metabolic-syndrome–related traits — a microbiome correlate of MetS biology, not a proof that changing stool taxa remits the syndrome.
Evidence for the claim as stated.
High-phenol virgin olive oil acutely changes inflammatory gene programs in MetS PBMCs.
In a 20-patient randomized crossover, high- vs low-phenol olive oil breakfasts altered 98 PBMC genes postprandially, including inflammation-linked transcripts — an acute meal effect, not long-term MetS remission.
Scope note — related MetS molecular theme, but stool microbiota/metabolites vs olive-oil PBMC transcripts
Limits the claim's scope: a different population, assay, or outcome.
Microbiome correlates, methylation-age risk, acute dietary transcript shifts, and SNP heritability all sit under MetS without sharing one assay or one intervention claim.
Evidence for the claim as stated.
Specific taxa and metabolite patterns associate with autoimmunity and metabolic syndrome risk contexts.
Bacteroides dorei dominance before autoimmunity and gut microbiota–metabolite links to metabolic syndrome show community composition correlating with host disease states beyond acute barrier leak.
Evidence for the claim as stated.
Acute viral severity markers, antibiotic perturbation experiments, and chronic microbiota–disease associations should not be collapsed into one “leaky gut causes X” claim.
Evidence for the claim as stated.
16S-style community profiles are sometimes paired with metabolites or, in infants, with shotgun metagenomes and host transcripts. A METSIM subset linked gut microbes to plasma metabolites and metabolic traits in Finnish men; six breast-fed versus six formula-fed infants showed diet-altered Firmicutes/Actinobacteria and many differentially expressed host immunity genes.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Cancer MR, pediatric T1D timing, and adult metabolic-trait associations all involve gut microbiota, but they answer different disease and design questions. Treating them as one interchangeable “gut microbiome disease effect” collapses distinct estimands.
Microbiome–metabolite associations in METSIM men and clamp/MRS insulin-resistance phenotypes share metabolic-syndrome territory while measuring different exposures and outcomes.
Microbiome correlates, methylation-age risk, acute dietary transcript shifts, and SNP heritability all sit under MetS without sharing one assay or one intervention claim.
Acute viral severity markers, antibiotic perturbation experiments, and chronic microbiota–disease associations should not be collapsed into one “leaky gut causes X” claim.
- Supports · Is severe COVID linked to leaky-gut plasma markers?
- Supports · Antibiotics hurt bee gut and survival
- Supports · B. dorei rises before T1D autoimmunity
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as a scope qualifier on Microbiome
Using Mendelian randomisation on gut-taxa genetic instruments, eleven stringent microbiome-to-cancer associations were reported (for example higher breast-cancer odds with Actinobacteria/Bifidobacteriales signals; Tyzzerella3 linked with higher lung adenocarcinoma but lower colorectal cancer risk).
Placed as a scope qualifier on Microbiome
In children who later developed type 1 diabetes autoimmunity, Bacteroides dorei became dominant in the gut community before persistent autoantibodies (mean diagnosis age about 16.8 months).
Placed as supporting evidence on Microbiome
In middle-aged men, gut microbiota composition was associated with plasma metabolites and metabolic-syndrome–related traits, placing the microbiome alongside genetics and lifestyle as a correlated host factor.
Placed as supporting evidence on Microbiome
Cancer MR, pediatric T1D timing, and adult metabolic-trait associations all involve gut microbiota, but they answer different disease and design questions. Treating them as one interchangeable “gut microbiome disease effect” collapses distinct estimands.
Related papers in this topic
Same topic cluster — not a recommendation engine.